DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2)

Phase 1

Completed

Conditions: Muscle Invasive Bladder Cancer

Interventions: Drug: Durvalumab
Drug: Oleclumab

First Posted Date: 2018-12-12

Last Posted Date: 2022-09-13

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 12

Registration Number: NCT03773666

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases

Phase 2

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: Trastuzumab
Drug: GDC-0084

First Posted Date: 2018-12-05

Last Posted Date: 2024-11-05

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 47

Registration Number: NCT03765983

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

GENetic Education Risk Assessment and TEsting Study

Not Applicable

Active, not recruiting

Conditions: Candidates for Hereditary Pancreatic Cancer Testing

Interventions: Other: Doxy.me genetic education +/- Color Genomics genetic education
Other: Color Genomics genetic education

First Posted Date: 2018-12-03

Last Posted Date: 2023-12-20

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 1000

Registration Number: NCT03762590

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Mobile Health App to Mitigate the Metabolic Effects of Androgen Deprivation Therapy

Not Applicable

Completed

Conditions: Prostate Cancer

Interventions: Other: Mobile Health App
Other: Usual care

First Posted Date: 2018-12-03

Last Posted Date: 2023-06-22

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 10

Registration Number: NCT03761160

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Prospective Study of the Prosigna Assay on Neoadjuvant Clinical Decision-making in Women With HR+/Her2- Breast Cancer

Active, not recruiting

Conditions: Breast Cancer

Interventions: Other: Prosigna PAM-50 assay

First Posted Date: 2018-11-21

Last Posted Date: 2024-04-16

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 60

Registration Number: NCT03749421

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Avelumab and Radiation in Muscle-Invasive Bladder Cancer

Phase 2

Recruiting

Conditions: Muscle Invasive Bladder Cancer
Bladder Cancer

Interventions: Drug: Avelumab
Radiation: Radiation

First Posted Date: 2018-11-20

Last Posted Date: 2024-11-27

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 24

Registration Number: NCT03747419

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL

Phase 1

Active, not recruiting

Conditions: Acute Lymphoblastic Leukemia ALL

Interventions: Drug: Ribociclib
Drug: Dexamethasone
Drug: Everolimus

First Posted Date: 2018-11-14

Last Posted Date: 2024-10-24

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 45

Registration Number: NCT03740334

Locations: 🇺🇸
Children's Healthcare of Atlanta, Atlanta, Georgia, United States
🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸
Nemours/Alfred I. duPont Hospital for Children, Wilmington, Delaware, United States

and more 9 locations

Testing Feasibility of Motivational Interviewing for Patient-Reported Cancer Pain Goals

Not Applicable

Completed

Conditions: Other Cancer

Interventions: Behavioral: Motivational Interviewing

First Posted Date: 2018-11-09

Last Posted Date: 2022-04-25

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 54

Registration Number: NCT03736746

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial

Phase 1

Terminated

Conditions: Acute Myeloid Leukemia
Myelodysplastic Syndromes

Interventions: Drug: Prexasertib
Drug: Mitoxantrone
Drug: Etoposide
Drug: Cytarabine

First Posted Date: 2018-11-08

Last Posted Date: 2019-06-12

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 2

Registration Number: NCT03735446

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Ex Vivo TCR αβ T Cell Depletion for Graft-Versus-Host Disease Prophylaxis in Mismatched Donor Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies

Phase 2

Terminated

Conditions: Hematologic Malignancy

Interventions: Device: ClinicMACs

First Posted Date: 2018-10-24

Last Posted Date: 2022-05-10

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 2

Registration Number: NCT03717480

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy